Brensocatib approved in the UK as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older – Insmed

The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted a marketing authorisation on on 20 February 2026 to to Insmed Netherlands B.V.   for  brensocatib (Brinsupri) to treat patients 12 years and older with non-cystic fibrosis bronchiectasis (NCFB) who have experienced two or more flare-ups or worsening of symptoms in the past 12 months.  Brensocatib is available as a tablet to be taken by mouth once a day.  A full list of side effects can be found in the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC), which will be published on the MHRA website within 7 days of approval.

Julian Beach, MHRA Executive Director, Healthcare Quality and Access, said:   “This is the first medicine licensed in the UK that specifically treats patients living with non-cystic fibrosis bronchiectasis. “As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.”